奥泰生物(688606.SH)：暂未考虑投资原料药、创新药领域

Group 1 - The company focuses on the POCT (Point of Care Testing) segment within the in vitro diagnostic industry [1] - The main business activities include the research, production, and sales of in vitro rapid diagnostic reagents, with the primary products being rapid diagnostic reagents [1] - The company is currently not considering investments in the raw material drug or innovative drug sectors [1]